CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 270 enrolled
Drug / intervention
Tofacitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03502616
NCT03502616Phase 3Completed
CompareCT.gov

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)

Pfizer·interventional·Posted Apr 18, 2018·Updated Sep 17, 2021

In Brief

A Phase 3 clinical trial evaluating Tofacitinib for Ankylosing Spondylitis. Completed, enrolled 270 participants across 99 sites in 14 countries.

Detailed Summary

The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesAustralia, Bulgaria, Canada, China, Czechia, France, Hungary, Israel, Poland, Russia, South Korea, Turkey (Türkiye), Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedApr 18, 2018
Enrollment StartJun 7, 2018
Primary CompletionDec 19, 2019
Study CompletionAug 20, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.2 years ago

Interventions

Tofacitinibdrug

Oral administration twice per day